NDAORALTABLET
Approved
Oct 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Tolazamide is an oral sulfonylurea tablet approved in 1984 for diabetes management. It works by stimulating pancreatic insulin secretion to lower blood glucose levels. This is a mature, first-generation antidiabetic agent now approaching loss of exclusivity.
LOE Approaching
As a mature product approaching LOE with moderate competitive pressure (30), teams are likely focused on defensive strategies and cost optimization rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job count reflects the mature, declining nature of this asset. Working on Tolazamide offers limited career advancement and is typically a transitional or specialized role rather than a growth opportunity.
Brand ManagerField Sales Representative
Worked on TOLAZAMIDE at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.